Jun 30, 2025
Gilead Sciences has received a highly anticipated approval from the FDA for its long-acting HIV prevention injection, YEZTUGO (lenacapavir), marking a significant advancement in HIV prevention. On June 18, 2025, the FDA approved YEZTUGO, an injectable HIV-1 capsid inhibitor, for use as pre-exposure prophylaxis (PrE...
Read More...
Understanding Bone Densitometers: Technology, Applications, and Impact on Bone Health
Nov 04, 2025
Wireless Brain Sensors: Revolutionizing Neuroscience and Healthcare
Oct 28, 2025
Discover How Learning Disability Treatment Landscape is Evolving with the Emergence of Digital Assistant Technologies
Jul 04, 2025
A New Era for Multiple Myeloma Treatment: Bispecific Antibodies Enter the Fray
Jun 10, 2025
-Agonist.png "Toll-like Receptors Agonist")
Newsletter/Whitepaper